PCSK9 Inhibitors and the Risk of Vitiligo: A Mendelian Randomization Study
Journal of Investigative Dermatology · 2025
DOI: 10.1016/j.jid.2024.07.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2025. Verfasst von Tae-Jong Kang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Jeonbuk National University Medical School, Jeonju, South Korea. Hauptthemen laut MEDLINE: Vitiligo, PCSK9 Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Science, ICT and Future Planning.
Abstract (Originalsprache)
Lipid-lowering agents have been suggested as a therapeutic option for vitiligo on the basis of the potential pathogenic role of lipid metabolism abnormalities. We aimed to explore the impact of genetically proxied lipid-lowering agents on the risk of vitiligo and potentially associated mediators. GWAS summary statistics for European ancestry were extracted from the largest available meta-analysis for vitiligo: the Global Lipids Genetics Consortium for 7 lipid profiles and 2 large biobanks, UK Biobank and deCODE, for 4719 proteins. After identifying lipid-lowering agents with genetically proxied protective effects against vitiligo using lipid-lowering and protein-inhibition Mendelian randomization (MR) analyses, multivariable and 2-step MR analyses were conducted to identify potential mediators between lipid-lowering agents and vitiligo. Lipid-lowering MR indicated a potential role of PCSK9 in reducing the vitiligo risk (OR [95% confidence interval] = 0.71 [0.52-0.95]), which was replicated in PCSK9-inhibition MR analyses across 2 separate biobanks (UK Biobank: OR [95% confidence interval] = 0.82 [0.71-0.96]; deCODE: OR [95% confidence interval] = 0.78 [0.67-0.91]). Multivariable MR suggested that well-known lipid profiles do not mediate the relationship between PCSK9 and vitiligo, whereas 2-step MR analyses identified 5 potential protein mediators (CCN5, CXCL12, FCRL1, legumain, and FGF2). Hence, PCSK9 inhibitor may attenuate the vitiligo risk; PCSK9 and the potential protein mediators can serve as promising novel therapeutic targets for its effective treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Jeonbuk National University Medical School, Jeonju, South Korea.
- Basgenbio, Seoul, South Korea.
- Department of Medical Informatics, Jeonbuk National University, Jeonju, South Korea; Department of Otorhinolaryngology-Head and Neck Surgery, Jeonbuk National University Medical School, Jeonju, South Korea; Research Ins…
- Department of Dermatology, Jeonbuk National University Medical School, Jeonju, South Korea; Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National Unive…
Förderung
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning
Zitieren
APA
Kang, T. J., Lee, S. Y., Yoon, S., Kim, E. G., Kim, J. O., Kim, J. S., Park, J., & Nam, K. H. (2025). PCSK9 Inhibitors and the Risk of Vitiligo: A Mendelian Randomization Study. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2024.07.021
Vancouver
Kang TJ, Lee SY, Yoon S, Kim EG, Kim JO, Kim JS, et al. PCSK9 Inhibitors and the Risk of Vitiligo: A Mendelian Randomization Study. Journal of Investigative Dermatology. 2025. doi:10.1016/j.jid.2024.07.021
BibTeX
@article{Kang2025,
author = {Kang, Tae-Jong and Lee, Sun Yeop and Yoon, Sanghyuk and Kim, Eun Gyo and Kim, Jung Oh and Kim, Jong-Seung and Park, Jin and Nam, Kyung-Hwa},
title = {PCSK9 Inhibitors and the Risk of Vitiligo: A Mendelian Randomization Study},
journal = {Journal of Investigative Dermatology},
year = {2025},
doi = {10.1016/j.jid.2024.07.021}
}
EUVIMED